This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Merck & Co., Inc.
Drug Names(s): daptomycin for injection, Cidecin, MK-3009
Description: Cubicin (daptomycin) is the first cyclic lipopeptide. The mechanism of action of daptomycin is unlike that of any other antibacterial agent. The hydrophobic tail of the molecule is inserted irreversibly into the cell membrane of Gram-positive bacteria in a process that requires physiologic levels of calcium. Subsequently, it is postulated that oligomers are formed that create a K+ channel in themembrane, leading to loss of K+ and membrane depolarization. Depolarization of the membrane is followed rapidly by cell death, suggesting that this is the major mechanism ofaction.
Daptomycin exhibits good activity against methicillin-sensitive and methicillin-resistant Staphylococcus aureus and streptococci; moderate activity against enterococci (including VRE); and poor activity against Gram-(-) bacteria.
Deal Structure: Revenue splits for this drug are BioMedTracker estimates.
In November 1997, Cubist entered into a license agreement with Eli Lilly that was amended and restated in October 2000, and pursuant towhich Cubist acquired exclusive worldwide rights to develop, manufacture and market Cubicin. In exchange for such license, Cubist paid anupfront license fee in cash and, if certain drug development milestones were achieved, agreed to pay milestone payments by issuing shares ofcommon stock to Eli Lilly. In addition, Cubist is required to pay royalties to Eli Lilly on worldwide sales of Cubicin. In July 2003, Cubistentered into an amendment to the restated license agreement with Eli Lilly and issued to Eli Lilly 723,619 shares of common stock valued at $8.0 million, in consideration for a 1% reduction in the royalty rates under the original license agreement. In March 2005, Cubist entered into a second amendment tothe license agreement with Eli Lilly and issued to Eli Lilly...See full deal structure in Biomedtracker
Partners: Eli Lilly & Company Novartis AG AstraZeneca PLC Royalty Pharma AG DRI Capital Inc.
Additional information available to subscribers only: